Please login to the form below

Not currently logged in
Email:
Password:

adalimumab

This page shows the latest adalimumab news and features for those working in and with pharma, biotech and healthcare.

Latest news

More from news
Approximately 20 fully matching, plus 194 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Covid-19: how is it affecting prescribing patterns?

    From March 2019, use of on-patent Etanercept, Adalimumab and Rituximab went down, while the Adalimumab biosimilar went up and so did Etanercept and Rituximab biosimilars.  This is to be expected

  • NHS medicines optimisation milestone

    that Adalimumab has been opened up to competition from cheaper rivals in Europe. ... prepare for the patent expiry of Adalimumab, which has the highest global turnover of any medicine,.

  • The Biosimilar Challenge

    These include the infliximab biosimilars Inflectra and Remsima, the etanercept biosimilar Benepali (launched last year) and biosimilars to adalimumab, filgrastim and bevacizumab preparing to launch on the horizon. .

  • Biosimilars: Getting the flock to market

    The greatest attraction, naturally, is high-revenue anti-TNF agents like MabThera (rituximab) and Humira (adalimumab), for many years the world's most valuable drug.

  • Wilmington Healthcare Wilmington Healthcare

    Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry.

More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
11 London

The biggest problems facing humanity today are health-related, and the health of people, animals and our planet are inextricably linked. ...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....